Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: NAROPIN

Summary for Tradename: NAROPIN

Suppliers: see list3
patent expirations by year for

Pharmacology for Tradename: NAROPIN

Drug ClassAmide Local Anesthetic
Physiological EffectLocal Anesthesia

Clinical Trials for: NAROPIN

Intraperitoneal Ropivacaine Nebulization for Pain Control After Laparoscopic Surgery
Status: Completed Condition: Laparoscopic Cholecystectomy

A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block
Status: Recruiting Condition: Upper Extremity Fracture

Interscalene Nerve Blocks With Ropivacaine Alone, With Dexamethasone, Plus Systemic Dexamethasone
Status: Withdrawn Condition: Pain

Ropivacaine Hypobaric Spinal Anaesthesia in Traumatic Hip Surgery
Status: Completed Condition: Femoral Neck Fracture

A Comparison of Postoperative Analgesic Nerve Block Ropivacaine Concentrations
Status: Active, not recruiting Condition: Total Hip Arthroplasty; Postoperative Pain

Intraperitoneal Ropivacaine Nebulization for Pain Control After Gynecologic Laparoscopic Surgery
Status: Completed Condition: Ovarian Cysts

Ropivacaine Versus Ropivacaine Plus Mepivacaine for Sciatic Block
Status: Completed Condition: Subgluteal Sciatic Block

Surgical Pain Control With Ropivacaine by Atomized Delivery
Status: Recruiting Condition: Pain

Trial Comparing the Onset and Duration of Ultrasound Guided Supraclavicular Nerve Blocks Using Ropivacaine Versus Ropivacaine-Chloroprocaine Mixture
Status: Completed Condition: Pain

Effects of Epidurally Administered Ropivacaine Concentration on the Hemodynamic Parameters
Status: Recruiting Condition: Epidural Anesthesia; Ropivacaine Concentration; Hemodynamics

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa
ropivacaine hydrochloride
INJECTABLE;INJECTION020533Sep 24, 1996RXNo5,670,524<disabled>YY<disabled>
Fresenius Kabi Usa
ropivacaine hydrochloride
INJECTABLE;INJECTION020533Sep 24, 1996RXNo5,834,489<disabled>YY<disabled>
Fresenius Kabi Usa
ropivacaine hydrochloride
INJECTABLE;INJECTION020533Sep 24, 1996RXYes5,670,524<disabled>YY<disabled>
Fresenius Kabi Usa
ropivacaine hydrochloride
INJECTABLE;INJECTION020533Sep 24, 1996RXYes5,834,489<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NAROPIN

Drugname Dosage Strength RLD Submissiondate
ropivacaine hydrochlorideInjection2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vialsNaropin11/13/2006

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology